Hymecromone clinical trial is cautiously positive

Robyn Kalda
Jul 7, 2025
1 min read

A very small (16 patients) phase 2a clinical trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) looked at whether hymecromone, a drug that might help blood vessels, had any promising effects.

Overall, the results weren't statistically significant, but half the patients treated with hymecromone improved their six-minute walk distance by 66m and had improved quality of life. Researchers concluded that a larger trial is warranted.

Read the Thorax article

Recent Posts

Promising results for drug candidate CS1

This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with d

Using sotatercept off-label in children

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients

Phase 1 trial of treprostinil prodrug patch succeeds

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a

Comments